Specifically, CD73 has been investigated as a prognostic biomarker for clinical outcomes in several solid tumors, including lung cancer, nasopharyngeal carcinoma, pancreatic cancer, esophageal carcinoma, thyroid carcinoma, gastric adenocarcinoma, and intrahepatic cholangiocarcinoma [35, 146, 156, 158–161]. Here, NT5E is linked to lung carcinoma.